Company attributes
Other attributes
Autolus develops and commercializes engineered T-cell immunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.
T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes. The company has a collaboration partnership with AbCellera Biologics Inc. for a project in antibody discovery.
Autolus is developing AUTO1, a programmed T cell therapy targeting CD19 to treat acute lymphoblastic B cell leukemia (ALL). The therapy designed to reduce the risk of severe cytokine release syndrome, is in a Phase I clinical trial as of 2019. Cytokine release syndrome is a condition that can occur after immunotherapy threatment and that can be life threatening. The therapy can cause immune cells to release a large release of cytokines into the blood and lead to symptoms like fever, nausea, headache, rask, rapid hearbeat, low blood pressure and trouble breathing. AUTO1 uses a novel CD19 binder that allows rapid disengagement of CAR T cells after target cell encounter and kill.
Pre-clinical and clinical data from an ongoing Phase I CARPALL trial of AUTO1 were published in Nature Medicine in 2019. In the Phase I clinical trial 86% of the pediatric ALL patients (n=14) showed molecular complete remission after a single dose with a median duration of remission of 7.4 months and no severe cytokine release syndrome.
AUTO2 is a programmed T cell therapy with two targets, for the treatment of relapsed or refractory multiple myeloma. AUTO2 is in PhaseI/II clinical trials as of 2019.
AUTO3 is a dual-targeting programmed T cell therapy for treating relapsed or refractory diffuse large B-cell lymphoma, which is in Phase I/II clinical trials as of 2019.
AUTO4 is a programmed T cell therapy for treatment of peripheral T-cell lymphoma and is in Phase I/II clinical trials as of 2019.
AUTO6 is a programmed T cell therapy for treatment of neuroblastoma.
